Health Trials

Lead-212 PSV359 Therapy for Patients With Solid Tumors

ConditionsPancreatic Ductal AdenocarcinomaGastric CancerEsophageal CancerColorectal CancerOvarian CancerHead and Neck CancerSarcomaMesothelioma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-90
SponsorPerspective Therapeutics

About this trial

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Eligibility criteria

Qualifiers

Aged ≥ 18 years

Satisfactory organ function as determined by laboratory testing

Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1

Life expectancy > 3 months

Disqualifiers

Known hypersensitivity to the active agent or any of the excipients

Active secondary malignancy

Pregnancy or breastfeeding a child

Known brain metastases

Trial design

Treatments tested in this trial

  • [203Pb]Pb-PSV359
  • [212Pb]Pb-PSV359

Treatment groups

112 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Perspective Therapeutics

Lead sponsor

Source ClinicalTrials.gov